11/2024. Clinical Trial with Birch-Mannan Conjugates
Allergy publishes results of a phase 3 clinical trial of mannan conjugated birch pollen allergoids.
Birch pollen is a major cause of spring respiratory allergy in central and northern Europe. Mannan-conjugated allergoids represent a new generation of vaccines for specific immunotherapy targeting dendritic cells developed by INMUNOTEK.
The Phase 3 clinical trial was conducted in Germany and evaluated the efficacy and safety of birch mannan allergoids administered subcutaneously in a short 5-dose schedule prior to the pollen season. The chosen dose was established in a previous study.
The published results confirm the safety and efficacy of mannan conjugated allergoids in a short regimen.
More information here.










